Jove
Visualize
Contact Us

Related Experiment Videos

The neuroleptic malignant syndrome.

W M O'Neill1

  • 1St Thomas' Hospital, London, UK.

Clinical Oncology (Royal College of Radiologists (Great Britain))
|July 1, 1990
PubMed
Summary

Neuroleptic malignant syndrome is a dangerous complication of dopamine antagonist drugs used in advanced cancer care. Early diagnosis is crucial, as symptoms can mimic other serious conditions, leading to underestimation of its true incidence.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The cognitive and psychomotor effects of morphine in healthy subjects: a randomized controlled trial of repeated (four) oral doses of dextropropoxyphene, morphine, lorazepam and placebo.

Pain·2000
Same author

A validated method for the determination of paracetamol and its glucuronide and sulphate metabolites in the urine of HIV+/AIDS patients using wavelength-switching UV detection.

Journal of pharmaceutical and biomedical analysis·1999
Same author

Cancer pain.

Middle East journal of anaesthesiology·1996
Same author

Questions of training--choice or force?

Palliative medicine·1996
Same author

The cognitive and psychomotor effects of opioid analgesics. I. A randomized controlled trial of single doses of dextropropoxyphene, lorazepam and placebo in healthy subjects.

European journal of clinical pharmacology·1995
Same author

The cognitive and psychomotor effects of opioid analgesics. II. A randomized controlled trial of single doses of morphine, lorazepam and placebo in healthy subjects.

European journal of clinical pharmacology·1995
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Area of Science:

  • Pharmacology
  • Oncology
  • Neurology

Background:

  • Neuroleptic malignant syndrome (NMS) is a severe adverse drug reaction.
  • Dopamine antagonist medications are frequently used for symptom management in advanced cancer.
  • The syndrome's potential severity and fatality are significant concerns in palliative care.

Observation:

  • The true incidence of NMS is likely underestimated.
  • Clinical presentation of NMS can be mistaken for infection or disease progression.
  • Diagnostic challenges complicate the timely recognition of NMS.

Findings:

  • NMS is a critical complication associated with neuroleptic and dopamine antagonist therapies.
  • Underdiagnosis contributes to the perceived low incidence of this serious condition.
  • Mimicry of other pathologies presents a diagnostic hurdle.

Implications:

  • Increased awareness and diagnostic vigilance for NMS are essential in oncology.
  • Improved diagnostic criteria and recognition protocols may be needed.
  • Understanding NMS is vital for optimizing safety in advanced cancer symptom control.

Related Experiment Videos